Latest / Bloomberg Law / Cancer Concerns Over Monsanto’s Roundup Threaten Deal (Audio)
Transcript
- 0:00Speaker 1: The herbside. Glypha state isn't everything from bread and cookies
- 0:03Speaker 1: to corn and beer. Glyphas is the active ingredient in
- 0:07Speaker 1: Monsanto's round Up, the world's top weed killer. Does it
- 0:11Speaker 1: cause cancer? That's the question that's been asked for decades.
- 0:15Speaker 1: Monsanto is facing more than three hundred lawsuits by cancer
- 0:18Speaker 1: victims around the country who claimed to have developed non
- 0:21Speaker 1: Hodgkins lymphoma as a result of exposure exposure to round Up.
- 0:26Speaker 1: Environmental lawyer Robert F. Kennedy, Jr. Is one of the
- 0:29Speaker 1: attorneys representing several California families in the suits against Monsanto.
- 0:36Speaker 1: It seems, you know, not just strange, but almost senate
- 0:39Speaker 1: sterre that this company would be trying to see the
- 0:44Speaker 1: real risk of its product from the people are being bused.
- 0:48Speaker 1: Our guests are Katherine Sharkey, professor at n y U
- 0:51Speaker 1: Law School, and Peter Walman, Bloomberg News investigative reporter. Katherine.
- 0:56Speaker 1: The World Health Organization's International Agency for Search on Cancer
- 1:01Speaker 1: classified Glypha state as a probable human carcinogen this month,
- 1:06Speaker 1: California became the first state to list it as a
- 1:08Speaker 1: known carcinogen. The e PAS conclusion has been that it's
- 1:12Speaker 1: unlikely to cause cancer. Where is the weight of the evidence? Uh,
- 1:19Speaker 1: So that's a great question. It will be contested in
- 1:21Speaker 1: these rash of lawsuits. UM. I can say that there
- 1:25Speaker 1: are interesting issues with respect to the role of states
- 1:30Speaker 1: regulating things like pesticides in ways that might challenge federal oversight.
- 1:35Speaker 1: So it's happening in this case, it's happened in other
- 1:37Speaker 1: cases regarding pharmaceutical drugs, food labeling, etcetera. So UM, the
- 1:44Speaker 1: court will be deciding UM interestingly looking at findings from
- 1:49Speaker 1: both the International Agency for Research, but also looking at
- 1:53Speaker 1: the a p e p a s findings and and
- 1:56Speaker 1: ongoing work where they might revisit their findings. Eater. In
- 2:00Speaker 1: your very thorough story in Bloomberg Business Week, you talk
- 2:04Speaker 1: about a panel of outside scientists that e p A
- 2:08Speaker 1: convened to take a look at this issue. Tell us
- 2:11Speaker 1: about that and what has happened to the findings of
- 2:15Speaker 1: that panel. So that was a panel convened in December
- 2:19Speaker 1: UM and it looked at a an issue paper that
- 2:24Speaker 1: e p A Pesticide Office developed on the question of
- 2:28Speaker 1: carcinogenicity of glypha sate. Glyphosate, of course, is the active
- 2:33Speaker 1: ingredient in Roundup, which is Lonsanto's product that really owns
- 2:37Speaker 1: the herbicide industry all over the world. It's a very
- 2:43Speaker 1: highly selling product used by many many farmers. The peer
- 2:47Speaker 1: reviewers who gathered in December cast a lot of questions
- 2:50Speaker 1: about the e p A view of Glypha sade as
- 2:54Speaker 1: being relatively benign. As you mentioned, they view it as
- 2:58Speaker 1: an unlikely carcinogen. Well, a majority of these peer reviewers
- 3:04Speaker 1: from universities around the country said there was lots of
- 3:08Speaker 1: evidence that the e p A sort of glossed over
- 3:11Speaker 1: and smissed and raised a tremendous number of questions, especially
- 3:16Speaker 1: for an really a kind of a proform a peer review,
- 3:20Speaker 1: about the e p a's view how that will figure
- 3:23Speaker 1: in the e p A final analysis. Uh, Administrator Pruett,
- 3:27Speaker 1: who is the trump ep A boss. Nobody can know,
- 3:31Speaker 1: but UH, they have put those scientific questions in the record. Catherine,
- 3:37Speaker 1: the San Francisco federal judge who's presiding over the multi
- 3:40Speaker 1: district litigation unsealed documents that raised questions about the safety
- 3:48Speaker 1: and research practices of Monsanto, raised questions about possible collusion.
- 3:54Speaker 1: Tell us about what some of those documents talk about, right, Well, UM.
- 4:00Speaker 1: Just to back up just for a second, I think
- 4:02Speaker 1: one thing that was just said that's really important is UM,
- 4:04Speaker 1: what kind of administrative record there is that UM then
- 4:09Speaker 1: litigants can bring into various disputes. They will bring these
- 4:12Speaker 1: into disputes like the one that's ongoing on causation. They
- 4:15Speaker 1: will also bring them in I would think whether there
- 4:18Speaker 1: if there are future disputes down the road about whether
- 4:21Speaker 1: the State of California could go ahead and regulate even
- 4:24Speaker 1: if the e PA decides it doesn't want to write,
- 4:27Speaker 1: these will be important UM for those purposes as well.
- 4:31Speaker 1: So my take on the judge in this multi district
- 4:35Speaker 1: litigation is he's shown a kind of skepticism already about
- 4:39Speaker 1: various of these agency findings by deciding to put these
- 4:43Speaker 1: up UM, to unseal them, to put them up to scrutiny. Peter.
- 4:49Speaker 1: One thing that your article talks about that I found
- 4:51Speaker 1: very striking with that this office, the Office of Pesticide
- 4:54Speaker 1: Programs at the e p A that makes the decision
- 4:56Speaker 1: on on UH this pesticide gets almost its operating budget
- 5:01Speaker 1: from industry. Can you tell us a little bit about
- 5:05Speaker 1: specifically with regard to mont Santo, what is Monsanto's relationship
- 5:10Speaker 1: with this office, well, that was brought under scrutiny by
- 5:14Speaker 1: the documents revealed or i should say unsealed in the
- 5:19Speaker 1: California UM federal court matter in San Francisco, where the
- 5:23Speaker 1: judge unsealed documents that showed Monsanto had quite a good
- 5:28Speaker 1: relationship with the person reviewing the Carsoner genicity in two
- 5:32Speaker 1: thousand and fifteen. There was very friendly banter and some emails.
- 5:37Speaker 1: At one point the e p A person whose name
- 5:40Speaker 1: is Jess Rowland said he should get a medal if
- 5:44Speaker 1: he's able to kill another study that a different federal
- 5:49Speaker 1: agency under the c d C in Atlanta was going
- 5:53Speaker 1: to undertake UM. So they had a very close relationship.
- 5:57Speaker 1: As far as Monsanto's related ship with UM, the Office
- 6:02Speaker 1: of Peticide Programs in e p A, it isn't that
- 6:06Speaker 1: different than any other pesticide manufacturer. The fact is they
- 6:11Speaker 1: follow the law and perhaps under their own influence, they
- 6:15Speaker 1: were able to influence Congress when they set these laws
- 6:17Speaker 1: up to basically rely on the industry to provide all
- 6:22Speaker 1: of the data in the various health effects reviews that
- 6:25Speaker 1: the EPA does. So Monsanto in the case of glyph
- 6:29Speaker 1: estate is the one paying the scientists deciding what to
- 6:34Speaker 1: submit to the e p A for review, and has
- 6:37Speaker 1: a tremendous influence over the process in that way. And
- 6:41Speaker 1: a number of the documents that came out in the
- 6:43Speaker 1: federal court matter have shown that they're very let's say,
- 6:49Speaker 1: they use a lot of discretion as to what scientists
- 6:52Speaker 1: they use, who they pay for the information, what what
- 6:55Speaker 1: they publish, what they give to the e p A.
- 6:58Speaker 1: And you can imagine their millions, really billions of dollars
- 7:02Speaker 1: writing on that scientific review. So they're very careful about
- 7:06Speaker 1: what the e p A. S s Catherine in about
- 7:09Speaker 1: a minute. The question in the federal cases, according to
- 7:14Speaker 1: the judge, is not going to be about glypha state,
- 7:18Speaker 1: but rather about round up, and so tell us what
- 7:22Speaker 1: the distinction is there. Well, as I understand it, it's um.
- 7:26Speaker 1: The roundup has various additives and other um chemicals that
- 7:32Speaker 1: are added in as well. And so I think that
- 7:34Speaker 1: the judges suggesting that they're going to be looking specifically
- 7:38Speaker 1: at data and studies that are going to be looking
- 7:40Speaker 1: at the effect of roundup and not just glypha state.
- 7:44Speaker 1: Although it's hard to believe that the findings that are
- 7:48Speaker 1: of relevance to whether glypha state has carcinergic that carcinogenic
- 7:53Speaker 1: um consequences would not be relevant. Just one one quick
- 7:56Speaker 1: note because I'm just to emphasize this point. Not only
- 7:59Speaker 1: the e p A at the f d A when
- 8:01Speaker 1: it's approving drugs, it also relies on manufacturer studies, etcetera.
- 8:05Speaker 1: And one of the things to keep in mind is
- 8:07Speaker 1: that what the court will have to do here when
- 8:10Speaker 1: it's dealing with an area that's regulated by federal regulators
- 8:14Speaker 1: is decide how much scrutiny you know to uncover Captain.
- 8:17Speaker 1: We will have to leave it there. This topic deserves
- 8:20Speaker 1: a lot of time, and we'll give it some more
- 8:22Speaker 1: in the future. That's Katherine shark Kee, Professor n y
- 8:24Speaker 1: U Law and Peter Waldman, Bloomberg News investigative reporter,